Promising cocktail targets deadly lymphoma mutation
NCT ID NCT07240194
First seen Nov 20, 2025 · Last updated Jun 23, 2026 · Updated 25 times
Summary
This phase 2 trial tests a combination of three drugs—glofitamab, a PD-1 inhibitor, and lenalidomide—in 24 adults with relapsed or refractory large B-cell lymphoma that has a TP53 gene mutation. The goal is to see if this mix can shrink tumors or make them disappear. The study is currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital with Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
glofitamab, PD-1 inhibitor, and lenalidomide
What this could lead to
If this works, it could offer a new treatment option for people with a hard-to-treat form of lymphoma that has not responded to standard therapies.
What could go wrong
This is a small, early-phase trial with only 24 participants, so results may not apply to everyone. The combination may cause side effects like cytokine release syndrome, and it is not yet known if it will improve survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.